Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 11/2013

01-11-2013 | Letter to the Editor

Pharmaceutical Sales Representatives and Patient Safety

Author: Donald W. Light, PhD

Published in: Journal of General Internal Medicine | Issue 11/2013

Login to get access

Excerpt

T o the Editor: In the first study to use identical data collection methods over the same period in three different jurisdictions, Mintzes et al. found that 98 % of the time, pharmaceutical reps failed to provide minimally adequate safety information about drugs to physicians.1 Worse, serious harms were rarely mentioned for drugs identified as harmful, and companies kept promoting them. This represents systematic untruthful abuse of First Amendment commercial free speech. …
Literature
1.
Mintzes B, Lexchin J, Sutherland J, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med. doi:10.​1007/​s11606-013-2411-7.
2.
Spurling GK, Mansfield PR, Montgomery BD. Information from pharmaceutical companies and the quality, quantity and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010;7:e1000352.PubMedCrossRef
3.
Light D. Bearing the risks of prescription drugs. Ch 1. In: Light D, ed. The risks of prescription drugs. New York: Columbia University Press; 2010.
4.
Light D, Lexchin J. Pharmaceutical R&D—what do we get for all that money? BMJ. 2012;344:e4348.CrossRef
5.
Levine S, Campen D, Millares M, Barrueta A. Kaiser Permanente’s prescription drug benefit. Heal Aff. 2000;19:185–90.CrossRef
Metadata
Title
Pharmaceutical Sales Representatives and Patient Safety
Author
Donald W. Light, PhD
Publication date
01-11-2013
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 11/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2559-1

Other articles of this Issue 11/2013

Journal of General Internal Medicine 11/2013 Go to the issue

Capsule Commentary

Capsule Commentary on McDaniel et al., Physicians Criticizing Physicians to Patients

Original Research

Physicians Criticizing Physicians to Patients

Letter

Electronic Health Records and the Increasing Complexity of Medical Practice

Original Research

Primary Care Clinicians’ Recognition and Management of Depression: A Model of Depression Care in Real-World Primary Care Practice

Erratum

Erratum to: Community-Partnered Cluster-Randomized Comparative Effectiveness Trial of Community Engagement and Planning or Resources for Services to Address Depression Disparities

Reply

Pharmaceutical Sales Representatives and Patient Safety
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits